Texas AG Paxton fires off another lawsuit at Pfizer, this one over the company's COVID-19 vaccineCOVID-19 vaccine

01 Dec 2023
www.fiercepharma.com
VaccinePatent InfringementmRNA
Texas AG Paxton fires off another lawsuit at Pfizer, this one over the company's COVID-19 vaccine
Preview
Source: FiercePharma
Texas attorney general Ken Paxton is again trying to bring the heat against Pfizer, this time suing the company for its claims about its COVID-19 vaccineCOVID-19 vaccine.
Texas Attorney General Ken Paxton is going after Pfizer—again.
Less than two weeks after documents were unsealed showing that Texas has accused Pfizer and manufacturer Tris Pharma of providing a compromised ADHD medicine to the state, Paxton has sued Pfizer for “unlawfully misrepresenting the effectiveness” of the company’s COVID-19 vaccineCOVID-19 vaccine, Comirnaty.
Paxton, a Republican, says that Pfizer’s claim of 95% efficacy against infection is misleading and overstated. His lawsuit (PDF) accuses Pfizer of conducting a campaign to “intimidate the public into getting the vaccine” and argues the company “conspired to censor public discourse” on the shot.
The suit claims Pfizer has violated the Texas Deceptive Trade Practices Act and seeks more than $10 million in fines. Texas also aims to force Pfizer to stop making “misrepresentations” about its vaccine.
“The company believes that the state’s case has no merit,” Pfizer wrote in an emailed statement, adding that its representations of its vaccine have been “accurate and science-based.”
In May, Paxton announced that the state launched an investigation into whether Pfizer, Moderna and Johnson & Johnson conducted “gain-of-function” research and the possibility that the companies manipulated trial data.
Paxton’s office did not respond immediately to a question about whether the state would sue Moderna or Johnson & Johnson.
The COVID-19 vaccine lawsuit comes right after Paxton accused Pfizer and Tris Pharma of knowingly providing a compromised ADHD drug, Quillivant XR, to the state's Medicaid program. In response, Pfizer said it "believes that the state’s case has no merit and will move to dismiss the case in due course."
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.